11-04 :: April/May 2011


nanotimes


Companies Facts


35


technicians to supervise and train University interns as well as their award winning CermaClad™ high energy density, large area, high speed cladding tech- nology to apply these advanced coatings to various metal surfaces.


MesoCoat is a venture-backed nanotechnology ma- terials science company fast becoming a world leader in metal protection and repair through their revolu- tionary “long life” coating and “high speed” cladding technologies. The Company was a wholly owned subsidiary of Powdermet. In late 2009, MesoCoat sold a 34% interest to Abakan. With the latest round investment, Abakan’s interest in MesoCoat will incre- ase to over 71%.


http://mesocoat.com http://www.youtube.com/watch?v=W-PDbZWCKYI


M


olecular Targeting Technologies, Inc., (MTTI) has obtained an exclusive license from the


Massachusetts General Hospital for novel fluore- scence dyes developed by Scott Hilderbrand, Ph.D. Fangwei Shao, Ph.D., and Ralph Weissleder, Ph.D. M.D.


MTTI is a privately held US based biotechnology company founded to develop novel medical ima- ging products such as PSVue®


is the imaging of


for the diagnostic and


molecular imaging of cancer and bacterial infections. A leading indication for PSVue®


tumor cell death in response to chemotherapy. Early assessment of therapy at the molecular level would allow a change of treatment when therapy is inef- fective, thereby limiting unnecessary treatment and associated costs. In addition, MTTI develops fluore- scent probes and other research tools for use by the


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93